No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
BDX240719P240000
- 9.30
- +4.50+93.75%
15min DelayClose Jul 19 15:59 ET
9.30High9.30Low
9.30Open4.80Pre Close1 Volume48 Open Interest240.00Strike Price930.00Turnover0.00%IV0.02%PremiumJul 19, 2024Expiry Date9.26Intrinsic Value100Multiplier-1DDays to Expiry0.04Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma25.08Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- Daily
News
Here's Why Madison Investors Fund Sold Becton, Dickinson and Company (BDX)
Least Shorted S&P 500 Stocks in June
Looking Into Becton Dickinson's Recent Short Interest
Becton Dickinson's (NYSE:BDX) short percent of float has risen 17.65% since its last report. The company recently reported that it has 2.32 million shares sold short, which is 0.8% of all regular
With 87% Institutional Ownership, Becton, Dickinson and Company (NYSE:BDX) Is a Favorite Amongst the Big Guns
Key Insights Given the large stake in the stock by institutions, Becton Dickinson's stock price might be vulnerable to their trading decisions The top 22 shareholders own 50% of the company
Becton Dickinson Warns of Blood Culture Product Delays
UnitedHealth, Edwards Lifesciences, First Citizens Bank And More: CNBC's 'Final Trades'
Jim Lebenthal of Cerity Partners hyped UnitedHealth Group Incorporated (NYSE:UNH) as a "solid" healthcare company in the latest edition of CNBC's "Halftime Report Final Trades." On July 9, Cantor
Comments
$Becton Dickinson & Co(BDX.US$ GAME OVER stock.
Despite a dip in earnings, Becton Dickinson's high P/E ratio persists due to anticipated robust future growth, outpacing the broader market. Investors' confidence in the company's future earnings is high, indicating the share price is unlikely to drop significantly soon.
$Becton Dickinson & Co(BDX.US$ BD Receives FDA 510(k) Clearance for Potentially Transformative Fingertip Blood Collection Device
2
Dr. Silverman's extensive experience and zeal for innovation, evidence generation, clinical development, medical safety, and compliance is predicted to boost BD's innovation pipeline and foster improved, personalized care.
Market sentiment towards Becton, Dickinson and Company shows no major shift in the past year. However, the rise in total shareholder return hints at a growing positivity.
Read more